Stiripentol-d<sub>9</sub>

Stiripentol-d9

CAT N°: 28506
Price:

634.00 538.90

Stiripentol-d9 is intended for use as an internal standard for the quantification of stiripentol (Item No. 17781) by GC- or LC-MS. Stiripentol is a third-generation antiepileptic compound.{28852} It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing ?3 subunits and to a lower extent in those containing ?1 or ? subunits.{48495} It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.{28852,48496} Stiripentol (500 µM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.{28811} Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-d3-1-penten-5,5,5-d3-3-ol
  • Correlated keywords
    • GCMS LCMS deuterated deuterium anti-epileptic GABA A ? 3 ? 1 LDH 5 BCX2600 Diacomit
  • Product Overview:
    Stiripentol-d9 is intended for use as an internal standard for the quantification of stiripentol (Item No. 17781) by GC- or LC-MS. Stiripentol is a third-generation antiepileptic compound.{28852} It is a positive allosteric modulator of GABAA receptors, potentiating GABA-mediated activation to a greater extent in receptors expressing ?3 subunits and to a lower extent in those containing ?1 or ? subunits.{48495} It also inhibits GABA reuptake in vitro and increases the release of GABA in neonatal rat hippocampal slices.{28852,48496} Stiripentol (500 µM) inhibits lactate dehydrogenase (LDH), blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human LDH1 and LDH5.{28811} Formulations containing stiripentol have been used in the adjunctive treatment of seizures associated with Dravet syndrome.

We also advise you